2022年3月15日 · Our study revealed a significantly higher level of VEGF in the tears of patients with AMD compared with controls. The tear VEGF level has high sensitivity and specificity, and is...

2020年4月11日 · 年龄相关性黄斑变性(age-related maculardegeneration，AMD):由遗传和环境因素共同诱发的与年龄相关的一组黄斑疾病。 早期表现为玻璃膜疣;进展期分为干性AMD和湿性AMD。

湿性AMD（wet age-related macular degeneration, wet AMD）作为老年人群体的主要致盲原因，其主要病因为患者视网膜色素上皮细胞（Retinal pigmented epithelium cell, RPE cell）分泌过量的血管内皮生长因子（Vascular endothelial growth factor,...

Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.

Anti–vascular endothelial growth factor (VEGF) drugs are the first-line treatment for wet AMD, and they are injected into the eye. These drugs can slow disease progression but are expensive and require trained medical professionals to administer and monitor treatment response.

2022年6月25日 · Some 8.1 million people suffer from visual impairment due to neovascular age-related macular degeneration (nAMD) [1]. The main therapeutic target is vascular endothelial growth factor (VEGF),...

2024年11月8日 · 哌加他尼是一种高效结合VEGF的RNA适配体，于2004年被美国食品药品监督管理局（Food and Drug Administration，FDA）批准用于治疗nAMD，开启了抗VEGF治疗在眼科领域的新时代，但由于其不良反应明显以及疗效较差，目前临床应用相对较少 [11]。 临床常用的抗VEGF药物主要包括两大类：重组融合蛋白类（阿柏西普和康柏西普）和单克隆抗体类（贝伐单抗和雷珠单抗） [12-14]，具体见表1。 尽管多数患者在接受抗VEGF药物治疗后病情得到改善， …

2023年10月20日 · Neovascular age-related macular degeneration is primarily treated with anti-vascular endothelial growth factor (VEGF) drugs, whereas atrophic AMD is treated with only two complement inhibitors and has fewer approved drugs than neovascular AMD.

2023年7月25日 · Among these, vascular endothelial growth factor A (VEGFA; also known as VEGF) and its two tyrosine kinase receptors, VEGFR1 and VEGFR2, represent a key...

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens.